About this trial

This is an investigator led trial which will examine the role of a patient’s exhaled breath; if it can be used check the patient’s molecular response to immunotherapy in Non-Small Cell Lung Cancer.
To do this cfDNA will be extracted from patient EBC and Blood samples, a response will be defined as a 50% reduction in total cfDNA from the baseline sample acheived at either 3 or 6 week samples (or both).
There has been no previous reports of using patients’ breath samples of Patients with NSCLC to assess their response to treatment. In this trial an exhaled Breath and blood samples will be collected from eligible patients who complete informed consent before treatment for NSCLC starts and during their treatment at specific time points.

Patient Profile

Patients >=18 years old who have confirmed diagnosis of advanced NSCLC or locally advanced NSCLC deemed unsuitable for definitive therapy who is due to commence systemic treatment with either single agent immunotherapy (IO) or combination chemo/IO but no prior lines of systemic therapy for advanced NSCLC

Where’s this trial being run?

Beaumont Hospital and St James’s Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information


Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Number: 23-11
Full Title:

BRAND: Translational study examining the role of exhaled breath as a biomarker of response to immunotherapy in NSCLC

Principal Investigator: Prof Jarushka Naidoo with Dr David O’Reilly

This is an Investigator Led Trial

Recruitment Started: Global: N/A
Global Recruitment Target:
Ireland Recruitment Target: 108